JAMA Oncol:病人对癌症检测治疗的要求

2015-02-17 赵洲译 MedSci原创

JAMA Oncology近日刊文,报道了一项有关病人对癌症检测治疗的要求的研究。被采访的医生认为高昂的医疗费用主要是因为病人的需求,而非医生本身。然而,鲜有数据有关有需求的病人、病人需求的合理性已经医生对病人需求的依从性。研究人员对内科医生、研究院、执业护士和医生助理进行采访,询问他们病人是否做出对癌症检测治疗的需求以及类型和合理性。采访是在美国费城地区的三个肿瘤门诊进行的。 研究得出4个

JAMA Oncology近日刊文,报道了一项有关病人对癌症检测治疗的要求的研究。被采访的医生认为高昂的医疗费用主要是因为病人的需求,而非医生本身。然而,鲜有数据有关有需求的病人、病人需求的合理性已经医生对病人需求的依从性。研究人员对内科医生、研究院、执业护士和医生助理进行采访,询问他们病人是否做出对癌症检测治疗的需求以及类型和合理性。采访是在美国费城地区的三个肿瘤门诊进行的。

研究得出4个主要结果。(1)病人要求医学检测或治疗的频率;(2)所需求的检测或治疗的类型;(3)临床医生对这些要求的合理性的评价;(4)临床医生依从病人需求的频率。在受访的5050例医患之中,包括了3624名病人和60名医生。其中440例(占8.7%)要求医疗干预。临床医生允许了365例(占83%)适当的需求。仅有50例(占11.4%)是不适当的医疗干预。医生允许了7例不适当的医疗干预,仅占总数的0.14%。在440例病人需求中,216例要求影像扫描检查;68例要求姑息疗法,不包括化疗或辐射;60例要求实验室化验。

在肿瘤门诊中,出现了8.7%的病人对癌症检测或治疗的需求。临床医生认为大部分的需求在临床上是合理的。而不合理的需求仅占1%,并且医生很少同意。至少在肿瘤科,对检测或治疗有要求的病人并不常见,也不是医疗费用花费过多的重要部分。

原始出处:

Gogineni K, Shuman KL, Chinn D, Gabler NB, Emanuel EJ. Patient Demands and Requests for Cancer Tests and Treatments.JAMA Oncol. Published online February 12, 2015. doi:10.1001/jamaoncol.2014.197.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1765447, encodeId=52821e65447aa, content=<a href='/topic/show?id=dee3e139503' target=_blank style='color:#2F92EE;'>#癌症检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71395, encryptionId=dee3e139503, topicName=癌症检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Nov 03 17:22:00 CST 2015, time=2015-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864603, encodeId=5f931864603b3, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Apr 10 18:22:00 CST 2015, time=2015-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23677, encodeId=caeb236e73a, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:26:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17164, encodeId=5fec1e16400, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 23:11:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16650, encodeId=ea4416650b5, content=非常好的文章,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sat Feb 21 10:44:00 CST 2015, time=2015-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16571, encodeId=4667165e194, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Fri Feb 20 09:13:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16558, encodeId=a7b116558d6, content=?学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Thu Feb 19 23:30:00 CST 2015, time=2015-02-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1765447, encodeId=52821e65447aa, content=<a href='/topic/show?id=dee3e139503' target=_blank style='color:#2F92EE;'>#癌症检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71395, encryptionId=dee3e139503, topicName=癌症检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Nov 03 17:22:00 CST 2015, time=2015-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864603, encodeId=5f931864603b3, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Apr 10 18:22:00 CST 2015, time=2015-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23677, encodeId=caeb236e73a, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:26:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17164, encodeId=5fec1e16400, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 23:11:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16650, encodeId=ea4416650b5, content=非常好的文章,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sat Feb 21 10:44:00 CST 2015, time=2015-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16571, encodeId=4667165e194, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Fri Feb 20 09:13:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16558, encodeId=a7b116558d6, content=?学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Thu Feb 19 23:30:00 CST 2015, time=2015-02-19, status=1, ipAttribution=)]
    2015-04-10 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1765447, encodeId=52821e65447aa, content=<a href='/topic/show?id=dee3e139503' target=_blank style='color:#2F92EE;'>#癌症检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71395, encryptionId=dee3e139503, topicName=癌症检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Nov 03 17:22:00 CST 2015, time=2015-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864603, encodeId=5f931864603b3, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Apr 10 18:22:00 CST 2015, time=2015-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23677, encodeId=caeb236e73a, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:26:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17164, encodeId=5fec1e16400, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 23:11:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16650, encodeId=ea4416650b5, content=非常好的文章,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sat Feb 21 10:44:00 CST 2015, time=2015-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16571, encodeId=4667165e194, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Fri Feb 20 09:13:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16558, encodeId=a7b116558d6, content=?学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Thu Feb 19 23:30:00 CST 2015, time=2015-02-19, status=1, ipAttribution=)]
    2015-05-16 ljjj1053

    很不错学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1765447, encodeId=52821e65447aa, content=<a href='/topic/show?id=dee3e139503' target=_blank style='color:#2F92EE;'>#癌症检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71395, encryptionId=dee3e139503, topicName=癌症检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Nov 03 17:22:00 CST 2015, time=2015-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864603, encodeId=5f931864603b3, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Apr 10 18:22:00 CST 2015, time=2015-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23677, encodeId=caeb236e73a, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:26:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17164, encodeId=5fec1e16400, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 23:11:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16650, encodeId=ea4416650b5, content=非常好的文章,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sat Feb 21 10:44:00 CST 2015, time=2015-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16571, encodeId=4667165e194, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Fri Feb 20 09:13:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16558, encodeId=a7b116558d6, content=?学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Thu Feb 19 23:30:00 CST 2015, time=2015-02-19, status=1, ipAttribution=)]
    2015-02-27 xiaoai5777

    好文章,超赞

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1765447, encodeId=52821e65447aa, content=<a href='/topic/show?id=dee3e139503' target=_blank style='color:#2F92EE;'>#癌症检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71395, encryptionId=dee3e139503, topicName=癌症检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Nov 03 17:22:00 CST 2015, time=2015-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864603, encodeId=5f931864603b3, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Apr 10 18:22:00 CST 2015, time=2015-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23677, encodeId=caeb236e73a, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:26:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17164, encodeId=5fec1e16400, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 23:11:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16650, encodeId=ea4416650b5, content=非常好的文章,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sat Feb 21 10:44:00 CST 2015, time=2015-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16571, encodeId=4667165e194, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Fri Feb 20 09:13:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16558, encodeId=a7b116558d6, content=?学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Thu Feb 19 23:30:00 CST 2015, time=2015-02-19, status=1, ipAttribution=)]
    2015-02-21 orthoW

    非常好的文章,学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1765447, encodeId=52821e65447aa, content=<a href='/topic/show?id=dee3e139503' target=_blank style='color:#2F92EE;'>#癌症检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71395, encryptionId=dee3e139503, topicName=癌症检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Nov 03 17:22:00 CST 2015, time=2015-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864603, encodeId=5f931864603b3, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Apr 10 18:22:00 CST 2015, time=2015-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23677, encodeId=caeb236e73a, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:26:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17164, encodeId=5fec1e16400, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 23:11:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16650, encodeId=ea4416650b5, content=非常好的文章,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sat Feb 21 10:44:00 CST 2015, time=2015-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16571, encodeId=4667165e194, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Fri Feb 20 09:13:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16558, encodeId=a7b116558d6, content=?学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Thu Feb 19 23:30:00 CST 2015, time=2015-02-19, status=1, ipAttribution=)]
    2015-02-20 orthoW

    很不错学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1765447, encodeId=52821e65447aa, content=<a href='/topic/show?id=dee3e139503' target=_blank style='color:#2F92EE;'>#癌症检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71395, encryptionId=dee3e139503, topicName=癌症检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Tue Nov 03 17:22:00 CST 2015, time=2015-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864603, encodeId=5f931864603b3, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Apr 10 18:22:00 CST 2015, time=2015-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=23677, encodeId=caeb236e73a, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ac181616815, createdName=ljjj1053, createdTime=Sat May 16 19:26:00 CST 2015, time=2015-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17164, encodeId=5fec1e16400, content=好文章,超赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Fri Feb 27 23:11:00 CST 2015, time=2015-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16650, encodeId=ea4416650b5, content=非常好的文章,学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Sat Feb 21 10:44:00 CST 2015, time=2015-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16571, encodeId=4667165e194, content=很不错学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Fri Feb 20 09:13:00 CST 2015, time=2015-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=16558, encodeId=a7b116558d6, content=?学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f2fb1607679, createdName=orthoW, createdTime=Thu Feb 19 23:30:00 CST 2015, time=2015-02-19, status=1, ipAttribution=)]
    2015-02-19 orthoW

    ?学习了

    0

相关资讯

中国癌症现状调查:死亡人数占全球四分之一

2月4日是世界癌症日,这一天的设立标志着全球共同攻克癌症的决心与期盼。中国肿瘤发病情况究竟怎样?和其他国家有何不同?肿瘤治疗情况究竟如何?带着一系列问题,新华社记者去年以来深入医院、病房、研究院所、企业和有关部门采访,就肿瘤现状进行调研,试图一探究竟。 发病率与世界水平接近但死亡率高于世界水平 这是一个个曾经鲜活的生命:赵丽蓉、罗京、陈晓旭、姚贝娜…… 这是一组触目惊心的数字

CA:图说全新全球癌症统计数据

2015年2月4日,《CA:临床医师癌症杂志》(CA Cancer J Clin)在线公布了全球癌症统计数据。这是基于2012年癌症新发、死亡病例数统计(GLOBOCAN)得出,也是继2011年所公布的2008年统计数据后,时隔4年再次公布的最新结果,其意义可谓重大。我们对2008年和2012年统计数据进行了分析和对比(如下图),目的是使癌症发病、死亡的趋势一目了然。对比结果显示,全球范围

CA:全新全球癌症统计数据

全球癌症统计2015年2月4日,《CA:临床医生杂志》(CA Cancer J Clin)在线发布了《2012年全球癌症统计》报告。 这份报告对全球癌症负担进行了概述。报告中的资料是基于国际癌症研究机构(IARC)公布的2012年GLOBOCAN的全球癌症发病率和死亡率获得的。利用2012年GLOBOCAN的数据,并通过癌症登记点数据所估算的全球癌症新发例数为1410万,癌症死亡例数为820万。

STM:一种新的治疗癌症方法:电场送药

研究小组已经设计了一种新的靶向肿瘤的抗癌治疗方法,这一发现可能会对癌症患者的临床治疗有新的效果。 根据本周发表在《科学转化医学》杂志上的一项研究,所谓的例子电渗疗法,该技术可以选择特定区域进行高浓度化疗,从而减少损伤健康组织的风险。 生物医学工程与力学系和机械工程系助理教授说:“有许多药物面临的一大挑战是让他们去需要它们的地方。该技术主要是迫使药物直接通过肿瘤,使所有肿瘤细胞暴露在治疗区域内。

求证:性格与癌症也有关系吗

摘要:很多人认为,只要吃好、睡好、生活规律,癌症就会远离我们。而一些肿瘤专家经过长期临床观察,得出一个结论,除了遗传和生活方式外,性格与癌症也有密切关系,并称之为“癌症性格”。 癌症与性格真能扯上关系? 正文“癌症性格”近日,首都医科大学肺癌诊疗中心主任、首都医科大学宣武医院胸外科主任、中国癌症基金会控烟与肺癌防治部主任支修益在接受《中国科学报》记者采访时表示,“癌症性格”这一提法很早就